Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The price of Silexion Therapeutics Corp (NASDAQ: SLXN) closed at $1.94 in the last session, down -7.62% from day before closing price of $2.10. In other words, the price has decreased by -$7.62 from its previous closing price. On the day, 83662.0 shares were traded. SLXN stock price reached its highest trading level at $2.1374 during the session, while it also had its lowest trading level at $1.93.
Ratios:
We take a closer look at SLXN’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.85 and its Current Ratio is at 0.85.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLXN now has a Market Capitalization of 3109994 and an Enterprise Value of 16461319.
Stock Price History:
The Beta on a monthly basis for SLXN is 0.02, which has changed by -0.82395643 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, SLXN has reached a high of $122.02, while it has fallen to a 52-week low of $1.86. The 50-Day Moving Average of the stock is -23.54%, while the 200-Day Moving Average is calculated to be -96.31%.
Shares Statistics:
According to the various share statistics, SLXN traded on average about 785.81K shares per day over the past 3-months and 138680 shares per day over the past 10 days. A total of 1.24M shares are outstanding, with a floating share count of 1.02M. Insiders hold about 36.54% of the company’s shares, while institutions hold 8.09% stake in the company. Shares short for SLXN as of 1731628800 were 35842 with a Short Ratio of 0.26, compared to 1728950400 on 9885. Therefore, it implies a Short% of Shares Outstanding of 35842 and a Short% of Float of 3.08.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
